×
Cronos Group EBITDA 2017-2025 | CRON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cronos Group ebitda from 2017 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Cronos Group EBITDA 2017-2025 | CRON
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Cronos Group ebitda from 2017 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$67.7B
Zoetis (ZTS)
$65.3B
Daiichi Sankyo, - (DSNKY)
$46.2B
Takeda Pharmaceutical (TAK)
$45.9B
BeOne Medicines - (ONC)
$31.6B
Sandoz Group AG (SDZNY)
$25.8B
Summit Therapeutics (SMMT)
$21.3B
Merck (MKKGY)
$16.4B
Shionogi (SGIOY)
$15.2B
United Therapeutics (UTHR)
$13.6B
Neurocrine Biosciences (NBIX)
$12.4B
Orion OYJ (ORINY)
$10.8B
IPSEN (IPSEY)
$10.4B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Corcept Therapeutics (CORT)
$7.6B
Grifols, S.A (GRFS)
$7.3B
Stevanato Group S.p.A (STVN)
$7.2B
Ionis Pharmaceuticals (IONS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Crinetics Pharmaceuticals (CRNX)
$2.5B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.1B
Endo (NDOI)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.7B